

Laura J Havrilesky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4435270/publications.pdf>

Version: 2024-02-01

139
papers

4,495
citations

168829

31
h-index

134545

62
g-index

139
all docs

139
docs citations

139
times ranked

6029
citing authors

#	ARTICLE	IF	CITATIONS
1	Catastrophic health expenditures, insurance churn, and nonemployment among gynecologic cancer patients in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 384.e1-384.e13.	0.7	8
2	Out-of-network bills among privately insured patients undergoing hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 543.e1-543.e45.	0.7	1
3	Reducing non-surgical readmissions on a gynecologic oncology service. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
4	Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers. <i>Gynecologic Oncology</i> , 2022, 164, 288-294.	0.6	11
5	Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database. <i>Gynecologic Oncology</i> , 2022, 165, 309-316.	0.6	10
6	NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCK].. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10615-TPS10615.	0.8	2
7	Development of a predictive model for emergency room utilization and unanticipated hospital admission in patients receiving cancer treatment for solid tumor malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18674-e18674.	0.8	0
8	Association of Medicaid expansion with mortality from gynecologic cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 323-325.	0.7	6
9	Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. <i>Gynecologic Oncology</i> , 2021, 160, 169-174.	0.6	7
10	Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. <i>Targeted Oncology</i> , 2021, 16, 109-118.	1.7	3
11	Evaluation of pelvic washing specimens in patients with endometrial cancer: Cytomorphological features, diagnostic agreement, and pathologist experience. <i>Cancer Cytopathology</i> , 2021, 129, 517-525.	1.4	5
12	92741 Racial differences in patient-reported distress among women with endometrial cancer. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 86-87.	0.3	0
13	Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. <i>JCO Oncology Practice</i> , 2021, 17, e1639-e1648.	1.4	4
14	Chemotherapy discontinuation processes in a gynecologic oncology population. <i>Gynecologic Oncology</i> , 2021, 161, 508-511.	0.6	5
15	Risk and distribution of venous thromboembolic events during treatment for advanced endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17565-e17565.	0.8	0
16	Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 513.e1-513.e19.	0.7	5
17	Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 50-56.	0.6	1
18	A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service. <i>Gynecologic Oncology</i> , 2021, 162, 120-127.	0.6	2

#	ARTICLE	IF	CITATIONS
19	The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. <i>Gynecologic Oncology</i> , 2021, 162, 440-446.	0.6	2
20	Medicaid Expansion Reduced Uninsured Surgical Hospitalizations And Associated Catastrophic Financial Burden. <i>Health Affairs</i> , 2021, 40, 1294-1303.	2.5	0
21	Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1075-e1084.	1.4	10
22	Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100853.	0.3	0
23	Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 237.e1-237.e24.	0.7	22
24	Associations of Insurance Churn and Catastrophic Health Expenditures With Implementation of the Affordable Care Act Among Nonelderly Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124280.	2.8	8
25	Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002884.	1.2	2
26	Opportunities to Advance the Delivery of High-Quality, Goal-Concordant End-of-Life Care in Ovarian Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100699.	1.4	0
27	Cost-effectiveness of bacteriuria screening before urogynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2021, , .	0.7	0
28	The cost-effectiveness of ertapenem for the treatment of chorioamnionitis after cesarean delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 4096-4101.	0.7	3
29	Cell-free DNA for Down syndrome screening in obese women: Is it a cost-effective strategy?. <i>Prenatal Diagnosis</i> , 2020, 40, 173-178.	1.1	4
30	Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. <i>Gynecologic Oncology</i> , 2020, 156, 154-161.	0.6	8
31	Cost-effectiveness analysis comparing ðPARP inhibitors-for-all to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 483-490.	0.6	19
32	Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?. <i>Patient</i> , 2020, 13, 401-408.	1.1	15
33	Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1738-1747.	1.2	8
34	Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?. <i>Gynecologic Oncology</i> , 2020, 156, 568-574.	0.6	15
35	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	0.6	21
36	Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 491-497.	1.2	20

#	ARTICLE	IF	CITATIONS
37	Genetic counseling referrals after next generation sequencing testing.. Journal of Clinical Oncology, 2020, 38, 1515-1515.	0.8	0
38	Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2020, 38, 7074-7074.	0.8	2
39	An analysis of trends in prostate cancer treatment from a CMS database.. Journal of Clinical Oncology, 2020, 38, e19288-e19288.	0.8	0
40	Induction of Labor versus Scheduled Cesarean in Morbidly Obese Women: A Cost-Effectiveness Analysis. American Journal of Perinatology, 2019, 36, 399-405.	0.6	5
41	Gender variation in Medicare utilization and payments in gynecologic oncology. Gynecologic Oncology, 2019, 154, 602-607.	0.6	4
42	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer, 2019, 125, 4399-4406.	2.0	16
43	Reduction in opioid use and postoperative pain scores after elective laparotomy with implementation of enhanced recovery after surgery protocol on a gynecologic oncology service. International Journal of Gynecological Cancer, 2019, 29, 935-943.	1.2	25
44	Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. World Journal of Surgical Oncology, 2019, 17, 80.	0.8	25
45	A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery. Gynecologic Oncology, 2019, 153, 399-404.	0.6	13
46	Preferences of women with epithelial ovarian cancer for aspects of genetic testing. Gynecologic Oncology Research and Practice, 2019, 6, 1.	3.6	13
47	Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service. Gynecologic Oncology, 2019, 153, 385-390.	0.6	2
48	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2019, 152, 445-451.	0.6	3
49	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecologic Oncology, 2019, 154, 199-206.	0.6	23
50	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecologic Oncology, 2019, 153, 555-561.	0.6	19
51	Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecologic Oncology, 2019, 153, 376-380.	0.6	17
52	Radiation Records in the National Cancer Database: Variations in Coding and/or Practice Can Significantly Alter Survival Results. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	20
53	Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. Journal of Oncology Practice, 2019, 15, e1018-e1027.	2.5	2
54	U.S. Food and Drug Administrationâ€‘Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer. Obstetrics and Gynecology, 2019, 133, 795-802.	1.2	28

#	ARTICLE	IF	CITATIONS
55	Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act. <i>Brachytherapy</i> , 2019, 18, 115-121.	0.2	5
56	The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care. <i>Gynecologic Oncology</i> , 2018, 148, 12-18.	0.6	22
57	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 21-25.	0.7	3
58	Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 9-20.	0.4	15
59	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	0.6	8
60	Estimating the number of potential family members eligible for <i>BRCA1</i> and <i>BRCA2</i> mutation testing in a "Traceback" approach. <i>Genetic Epidemiology</i> , 2018, 42, 117-122.	0.6	6
61	Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States. <i>JAMA Oncology</i> , 2018, 4, 190.	3.4	30
62	Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act. <i>Journal of Oncology Practice</i> , 2018, 14, e92-e102.	2.5	34
63	Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2018, 151, 506-512.	0.6	10
64	Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions. <i>Gynecologic Oncology</i> , 2018, 151, 542-546.	0.6	19
65	High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis. <i>Brachytherapy</i> , 2018, 17, 906-911.	0.2	3
66	Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?. <i>Gynecologic Oncology</i> , 2017, 144, 125-129.	0.6	9
67	Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 144, 531-535.	0.6	10
68	Increasing utilization of intensity modulated radiation therapy in vulvar cancer: National Practice Patterns 2004-2012. <i>Journal of Radiation Oncology</i> , 2017, 6, 197-206.	0.7	0
69	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology</i> , 2017, 146, 373-379.	0.6	45
70	Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2017, 145, 549-554.	0.6	22
71	The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2017, 145, 185-191.	0.6	4
72	Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 535-540.	0.6	29

#	ARTICLE	IF	CITATIONS
73	The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 441-442.	0.6	0
74	Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act. <i>Gynecologic Oncology</i> , 2017, 146, 457-464.	0.6	29
75	Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. <i>Cancer</i> , 2017, 123, 4004-4012.	2.0	25
76	Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3116-3123.	0.7	17
77	Disparities in the surgical staging of high-grade endometrial cancer in the United States. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 1.	3.6	17
78	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e120-e129.	2.5	11
79	Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3999-4002.	0.8	14
80	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10
81	Is There a Role for Ovarian Cancer Screening in High-Risk Women?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1384-1386.	0.8	8
82	Tumor grade and chemotherapy response in endometrioid endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2016, 17, 3-6.	0.3	15
83	Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 13.	3.6	1
84	Performance of sentinel lymph node biopsy in high-risk endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2016, 17, 69-71.	0.3	44
85	Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. <i>Current Medical Research and Opinion</i> , 2016, 32, 453-458.	0.9	14
86	Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. <i>Molecular and Clinical Oncology</i> , 2016, 4, 399-404.	0.4	7
87	Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2016, 140, 184-190.	0.6	120
88	Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 13, 49-52.	0.3	3
89	Patient-reported outcomes as end points and outcome indicators in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 358-370.	12.5	55
90	Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2015, 139, 541-545.	0.6	47

#	ARTICLE	IF	CITATIONS
91	Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?. <i>Gynecologic Oncology</i> , 2015, 136, 43-47.	0.6	24
92	Vaginal Cuff Thermal Injury by Mode of Colpotomy at Total Laparoscopic Hysterectomy: A Randomized Clinical Trial. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 227-233.	0.3	9
93	A review of relative dose intensity and survival in patients with metastatic solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 203-210.	2.0	100
94	A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 293-299.	0.6	24
95	Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. <i>Gynecologic Oncology</i> , 2015, 136, 300-304.	0.6	34
96	Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer – An intriguing option in a population at risk for dying of complications of metabolic syndrome. <i>Gynecologic Oncology</i> , 2015, 138, 597-602.	0.6	14
97	Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study. <i>Gynecologic Oncology</i> , 2015, 138, 101-108.	0.6	13
98	Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 1004-1010.	0.3	14
99	Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. <i>Journal of the National Cancer Institute</i> , 2015, 107, 322.	3.0	16
100	Benefits and Harms of Breast Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1615.	3.8	473
101	A multi-institutional study of outcomes in stage III uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 139, 275-282.	0.6	25
102	Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. <i>Gynecologic Oncology</i> , 2015, 138, 694-699.	0.6	13
103	Can We Maximize Both Value and Quality in Gynecologic Cancer Care? A Work in Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e268-e275.	1.8	2
104	Patient preferences in advanced or recurrent ovarian cancer. <i>Cancer</i> , 2014, 120, 3651-3659.	2.0	68
105	Metformin is associated with improved survival in endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 438-442.	0.6	148
106	Cost of care using prophylactic negative pressure wound vacuum on closed laparotomy incisions. <i>Gynecologic Oncology</i> , 2014, 132, 684-689.	0.6	38
107	Palliative services enhance the quality and value of gynecologic cancer care. <i>Gynecologic Oncology</i> , 2014, 132, 1-2.	0.6	5
108	The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: Prevalence and prognostic significance. <i>Gynecologic Oncology</i> , 2014, 133, 28-32.	0.6	54

#	ARTICLE	IF	CITATIONS
109	Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients. <i>Gynecologic Oncology</i> , 2014, 133, 211-215.	0.6	25
110	Quality of life in ICON7: need for patients' perspectives. <i>Lancet Oncology</i> , The, 2013, 14, 183-185.	5.1	18
111	A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 128, 65-70.	0.6	89
112	Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 156-161.	0.6	94
113	Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 426-430.	0.6	57
114	How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. <i>Gynecologic Oncology</i> , 2013, 131, 140-146.	0.6	16
115	In Reply. <i>Obstetrics and Gynecology</i> , 2013, 122, 1114.	1.2	0
116	Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2013, 122, 139-147.	1.2	202
117	Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 631-634.	0.6	25
118	Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. <i>Cancer</i> , 2012, 118, 386-391.	2.0	14
119	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity. <i>Cancer</i> , 2011, 117, 545-553.	2.0	30
120	Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 160.e1-160.e7.	0.7	14
121	Cost Comparison Among Robotic, Laparoscopic, and Open Hysterectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2010, 116, 685-693.	1.2	162
122	Cost effectiveness of a test to detect metastases for endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 112, 526-530.	0.6	6
123	Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. <i>Gynecologic Oncology</i> , 2009, 113, 216-220.	0.6	101
124	Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 279-283.	0.6	24
125	Cost-effectiveness analysis of annual screening strategies for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 640.e1-640.e8.	0.7	28
126	Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. <i>Gynecologic Oncology</i> , 2008, 110, 374-382.	0.6	201

#	ARTICLE	IF	CITATIONS
127	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. <i>Gynecologic Oncology</i> , 2008, 111, 179-187.	0.6	38
128	Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4144-4150.	0.8	42
129	The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 401-405.	0.6	75
130	Outcomes in surgical stage I uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 677-682.	0.6	99
131	Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2007, 107, 211-218.	0.6	22
132	FDG-PET for management of cervical and ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 183-191.	0.6	245
133	Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 99, 689-695.	0.6	99
134	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. <i>Gynecologic Oncology</i> , 2004, 93, 429-434.	0.6	57
135	Weekly Low-Dose Carboplatin and Paclitaxel in the Treatment of Recurrent Ovarian and Peritoneal Cancer. <i>Gynecologic Oncology</i> , 2003, 88, 51-57.	0.6	72
136	The role of PET scanning in the detection of recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2003, 90, 186-190.	0.6	118
137	Predictors of clinical outcomes in the laparoscopic management of adnexal masses. <i>Obstetrics and Gynecology</i> , 2003, 102, 243-251.	1.2	55
138	Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3814-3825.	0.8	143
139	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. <i>Cancer</i> , 2001, 92, 2837-2844.	2.0	94